Notes And Other Explanatory Information [Abstract]

OSE Immunotherapeutics - Filing #5980970

Concept 2024-01-01 to
2024-12-31
Notes and other explanatory information [abstract]
Disclosure of cash and cash equivalents [text block]
2
Disclosure of commitments [text block]
ENTS
Disclosure of credit risk [text block]
13.3. Risque de crédit
Disclosure of deferred taxes [text block]
10.1.
Disclosure of employee benefits [text block]
8.6.
Disclosure of events after reporting period [text block]
E
Disclosure of finance income (cost) [text block]
CIER
Disclosure of financial assets held for trading [text block]
1
Disclosure of financial risk management [text block]
RS
Disclosure of general and administrative expense [text block]
8.4.
Disclosure of general information about financial statements [text block]
INFORMATIONS RELATIVES A L'ENTREPRISE PRESENTANT LES ETATS FINANCIERS
Disclosure of information about employees [text block]
Au 31 décembre 2024, l'effectif moyen s'élève à 56 contre 62 au 31 décembre 2023.
Disclosure of information about key management personnel [text block]
IEES
Disclosure of issued capital [text block]
NOTE 4 : CAPITAL
Disclosure of liquidity risk [text block]
é
Disclosure of material accounting policy information [text block]
ABLES
Disclosure of other current assets [text block]
2
Disclosure of other current liabilities [text block]
6.3.
Disclosure of property, plant and equipment [text block]
1
Disclosure of research and development expense [text block]
8.3.
Disclosure of revenue from contracts with customers [text block]
8.1.
Disclosure of share capital, reserves and other equity interest [text block]
3.10 Capitaux
Disclosure of tax receivables and payables [text block]
6.2.
Disclosure of trade and other payables [text block]
6.1.
Disclosure of trade and other receivables [text block]
2

Talk to a Data Expert

Have a question? We'll get back to you promptly.